drugset / Trial / NCT01234974
IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Observe the safety/tolerability and effectiveness in terms of response rate and duration of response of the combination pasireotide + everolimus in the treatment of patients with relapsed/refractory multiple melanoma.
Timeline
- Start
- 2010-12
- Primary completion
- 2012-12
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 10 mg | Oral |
| Subject | Pasireotide | Other / unclassified | 60 mg | Intramuscular |